Press Releases

BioIVT is contributing to four healthcare organizations this year, focusing on cancer, liver diseases, Alzheimer’s disease, and global health equity

BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it is making several charitable donations in December to honor its clients' commitment to medical research.

This year, BioIVT is recognizing four non-profit healthcare organizations that support exceptional research to eradicate diseases that affect millions of people. During December, BioIVT will highlight the work of, and make a financial contribution to, the following organizations: Cancer Research Institute, Global Liver Institute, Cure Alzheimer’s Fund, and PATH.

“2020 has been an incredibly challenging year. The COVID-19 pandemic has required medical researchers around the world to continue their studies, in spite of the requirement of socially distancing and other obstacles that had made a difficult assignment even harder. Balancing work and home life has never been tougher with closed schools, ever changing guidelines, and limited access to work facilities. Despite these constraints, we are seeing great global cooperation and medical breakthroughs occurring at a rapid rate,” said BioIVT Chief Executive Officer Jeffrey Gatz. “Our clients dedicate tremendous brain power, time, and resources to advance medical research and make a positive impact on human health. In honor of their hard work and important missions, BioIVT is making a financial contribution to these featured organizations that, like our clients, are relentlessly driving research forward.”

BioIVT’s chosen charities have broad, long-term goals that will benefit everyone. Cancer Research Institute supports researchers around the world who are developing immunotherapies to one day create a world without cancer. Global Liver Institute works to improve the lives of those affected by liver diseases, while also trying to eradicate the illnesses. Cure Alzheimer’s Fund supports research to prevent, slow the progression, and reverse Alzheimer’s disease. PATH’s goal is to improve health outcomes for more than 1.4 billion people worldwide through programs that expedite vaccine development and delivery, make high-impact diagnostic tools affordable, and improve access to drugs where they are needed most.

To learn more about research breakthroughs in these fields, and BioIVT’s associated portfolio areas, check out the company’s LinkedIn page at https://www.linkedin.com/company/bioivt and Twitter feed at https://twitter.com/BioIVT.

About BioIVT

BioIVT is a leading global provider of research models and value-added research services for drug discovery and development. We specialize in control and disease-state biospecimens including human and animal tissues, cell products, blood and other biofluids. Our unmatched portfolio of clinical specimens directly supports precision medicine research and the effort to improve patient outcomes by coupling comprehensive clinical data with donor samples. And as the premier supplier of hepatic products, including hepatocytes and subcellular fractions, BioIVT enables scientists to better understand the pharmacokinetics and drug metabolism of newly discovered compounds and their effects on disease processes. By combining our technical expertise, exceptional customer service, and unparalleled access to biological specimens, BioIVT serves the research community as a trusted partner in elevating science. For more information, please visit www.bioivt.com or follow the company on Twitter @BioIVT.